CEB-01

Phase 3Small molecule

BioMarin Pharmaceutical

CEB-01 is one of 46 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

PhenylketonuriaActive, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

PhenylketonuriaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

108 2

CEB-01

BioMarin Pharmaceutical

Phase 3

1 3

Medrol

Pfizer

Preclinical

1 4

Byetta

AstraZeneca

Preclinical

1 5

MS Contin

Merck & Co.

Preclinical

1 6

Active Comparator

Moderna

Preclinical

1 7

Secretin-Ferring

Ferring

Preclinical

1 8

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

2 9

Rybelsus

Pfizer

Preclinical

1 10

Gemcitabine/nab-Paclitaxel

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Pancreatic Cancer

NCT06538857

Q2 2029

Phase 2Recruiting

Resectable

NCT06986811

Clinical

Trials by Indication[1]

Resectable1 trial

CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours

Recruiting·CCEBIOTEX·Phase 2·NCT06986811·60 enrolled

Pancreatic Cancer1 trial

CEB-01 in Locally Resectable Pancreatic Cancer

Recruiting·CCEBIOTEX·Phase 2·NCT06538857·39 enrolled

Phenylketonuria1 trial

PEGVALIASE-LT: Pegvaliase Long-Term in PKU

Active, not recruiting· BioMarin Pharmaceutical logo

BioMarin Pharmaceutical·Phase 3·NCT04619056·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for CEB-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CEB-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CEB-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioMarin Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BioMarin Pharmaceutical

CEB-01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q2 2029

Trials by Indication[1]

Resectable1 trial

Pancreatic Cancer1 trial

Phenylketonuria1 trial

References

Drug Info

Quick Facts

Related News